Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Treatment of co-occurring substance use disorder and anxiety-related disorders in adults

Sudie E Back, PhD
Megan M Moran-Santa Maria, PhD
Section Editor
Murray B Stein, MD, MPH
Deputy Editor
Richard Hermann, MD


Substance use disorder (SUD) commonly co-occurs in anxiety-related disorders (in DSM-5 these include the anxiety disorders, trauma- and stressor-related disorders, and obsessive-compulsive and related disorders) [1-4]. The association between these disorders is multifaceted. Anxiety-related disorders may increase the risk for the development of SUDs, and may alter the presentation and treatment outcome of SUDs. SUDs may alter the presentation and outcome of treatment for anxiety-related disorders.

The complexity of these comorbidities highlights the importance of a comprehensive understanding of the symptoms of each disorder, proper diagnosis, and use of effective treatments as well as consideration of potentially toxic drug-drug interactions, medication abuse liability, and patient adherence.

In the revision of DSM-IV to DSM-5, PTSD was reclassified from an anxiety disorder to a “trauma and stressor-related” disorder and OCD was reclassified as an “obsessive-compulsive and related disorder” [5]. Diagnoses of substance abuse and substance dependence in DSM-IV were replaced by the single diagnosis, substance use disorder in DSM-5  

This topic reviews treatment of co-occurring substance use disorder and anxiety-related disorders. The epidemiology, pathogenesis, clinical manifestations, course, and diagnosis of co-occurring substance use disorder and anxiety-related disorders are described separately. Treatment of individual, noncomorbid anxiety-related disorders are described separately. Treatment of individual, noncomorbid substance use disorders are described separately. (See "Co-occurring substance use disorder and anxiety-related disorders in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis" and "Pharmacotherapy for obsessive-compulsive disorder in adults" and "Psychotherapy for obsessive-compulsive disorder in adults" and "Pharmacotherapy for panic disorder and agoraphobia in adults" and "Psychotherapy for panic disorder in adults" and "Pharmacotherapy for generalized anxiety disorder in adults" and "Pharmacotherapy for social anxiety disorder in adults" and "Pharmacotherapy for posttraumatic stress disorder in adults" and "Psychotherapy for posttraumatic stress disorder in adults" and "Pharmacotherapy for opioid use disorder" and "Treatment of cannabis use disorder" and "Pharmacotherapy for alcohol use disorder" and "Psychosocial treatment of alcohol use disorder" and "Brief intervention for unhealthy alcohol and other drug use" and "Cocaine use disorder in adults: Epidemiology, pharmacology, clinical manifestations, medical consequences, and diagnosis".)


Clinical trials have identified medications and psychotherapies that effectively treat individual, noncomorbid anxiety-related disorders as well as individual, noncomorbid substance use disorders (SUDs). However, evidence from clinical trials, described below, is generally inadequate to determine the effectiveness of these interventions in treating co-occurring anxiety-related disorders and SUDs.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Feb 2017. | This topic last updated: Fri Nov 07 00:00:00 GMT+00:00 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8.
  2. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:617.
  3. Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2007; 64:566.
  4. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004; 61:807.
  5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington 2013.
  6. Back SE. Toward an improved model of treating co-occurring PTSD and substance use disorders. Am J Psychiatry 2010; 167:11.
  7. Back SE, Killeen T, Foa EB, et al. Use of an integrated therapy with prolonged exposure to treat PTSD and comorbid alcohol dependence in an Iraq veteran. Am J Psychiatry 2012; 169:688.
  8. Mills KL, Teesson M, Back SE, et al. Integrated exposure-based therapy for co-occurring posttraumatic stress disorder and substance dependence: a randomized controlled trial. JAMA 2012; 308:690.
  9. Najavits L. Seeking Safety: A Treatment Manual for PTSD and Substance Abuse, Guilford Press, New York 2002.
  10. Hien DA, Cohen LR, Miele GM, et al. Promising treatments for women with comorbid PTSD and substance use disorders. Am J Psychiatry 2004; 161:1426.
  11. Najavits LM, Gallop RJ, Weiss RD. Seeking safety therapy for adolescent girls with PTSD and substance use disorder: a randomized controlled trial. J Behav Health Serv Res 2006; 33:453.
  12. Zlotnick C, Johnson J, Najavits LM. Randomized controlled pilot study of cognitive-behavioral therapy in a sample of incarcerated women with substance use disorder and PTSD. Behav Ther 2009; 40:325.
  13. Hien DA, Wells EA, Jiang H, et al. Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders. J Consult Clin Psychol 2009; 77:607.
  14. van Dam D, Ehring T, Vedel E, Emmelkamp PM. Trauma-focused treatment for posttraumatic stress disorder combined with CBT for severe substance use disorder: a randomized controlled trial. BMC Psychiatry 2013; 13:172.
  15. Brady KT, Dansky BS, Back SE, et al. Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: preliminary findings. J Subst Abuse Treat 2001; 21:47.
  16. Triffleman E, Carroll K, Kellogg S. Substance dependence posttraumatic stress disorder therapy. An integrated cognitive-behavioral approach. J Subst Abuse Treat 1999; 17:3.
  17. Triffleman E. Gender differences in a controlled pilot study of psychosocial treatments in substance dependent patients with post-traumatic stress disorder: Design considerations and outcomes. Alcohol Treat Q 2000; 18:113.
  18. Tuerk PW, Yoder M, Grubaugh A, et al. Prolonged exposure therapy for combat-related posttraumatic stress disorder: an examination of treatment effectiveness for veterans of the wars in Afghanistan and Iraq. J Anxiety Disord 2011; 25:397.
  19. Killeen TK, Back SE, Brady KT. The Use of Exposure-Based Treatment Among Individuals With PTSD and Co-occurring Substance Use Disorders: Clinical Considerations. J Dual Diagn 2011; 7:194.
  20. Brady KT, Sonne S, Anton RF, et al. Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res 2005; 29:395.
  21. Kranzler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Arch Gen Psychiatry 1994; 51:720.
  22. Tollefson GD, Montague-Clouse J, Tollefson SL. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol 1992; 12:19.
  23. Malcolm R, Anton RF, Randall CL, et al. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 1992; 16:1007.
  24. McRae AL, Sonne SC, Brady KT, et al. A randomized, placebo-controlled trial of buspirone for the treatment of anxiety in opioid-dependent individuals. Am J Addict 2004; 13:53.
  25. Randall CL, Thomas S, Thevos AK. Concurrent alcoholism and social anxiety disorder: a first step toward developing effective treatments. Alcohol Clin Exp Res 2001; 25:210.
  26. Randall CL, Johnson MR, Thevos AK, et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety 2001; 14:255.
  27. Bowen RC, D'Arcy C, Keegan D, Senthilselvan A. A controlled trial of cognitive behavioral treatment of panic in alcoholic inpatients with comorbid panic disorder. Addict Behav 2000; 25:593.
  28. Kushner MG, Sletten S, Thuras P, et al. Cognitive behavioral treatment of comorbid anxiety disorder in alcoholism treatment patients: Presentation of a prototype program and future directions. Journal of Mental Health 2006; 15:697.
  29. Fals-Stewart W, Schafer J. The treatment of substance abusers diagnosed with obsessive-compulsive disorder: an outcome study. J Subst Abuse Treat 1992; 9:365.
  30. Chatterjee CR, Ringold AL. A case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin. J Clin Psychiatry 1999; 60:617.
  31. Petrakis IL, Poling J, Levinson C, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biol Psychiatry 2006; 60:777.
  32. Haass-Koffler CL, McCance-Katz EF. Medication interactions. In: Substance Abuse: A comprehensive textbook, Ruis P, Strain E. (Eds), Lippincott, Williams & Wilkins, Philadelphia, PA 2011. p.730.
  33. Lehmann KA. Opioids: overview on action, interaction and toxicity. Support Care Cancer 1997; 5:439.
  34. Koski A, Ojanperä I, Vuori E. Interaction of alcohol and drugs in fatal poisonings. Hum Exp Toxicol 2003; 22:281.
  35. Martinotti G, Di Nicola M, Tedeschi D, et al. Efficacy and safety of pregabalin in alcohol dependence. Adv Ther 2008; 25:608.
  36. Kawano Y, Abe H, Kojima S, et al. Interaction of alcohol and an alpha1-blocker on ambulatory blood pressure in patients with essential hypertension. Am J Hypertens 2000; 13:307.
  37. Dennison SJ. Substance use disorders in individuals with co-occurring psychiatric disorders. In: Substance Abuse: A comprehensive textbook, Ruis P, Strain E. (Eds), ippincott, Williams & Wilkin, Philadelphia, PA 2011. p.721.
  38. Herbeck DM, Fitek DJ, Svikis DS, et al. Treatment compliance in patients with comorbid psychiatric and substance use disorders. Am J Addict 2005; 14:195.
  39. Pettinati HM. Improving medication adherence in alcohol dependence. J Clin Psychiatry 2006; 67 [suppl 14]:23.
  40. Brady KT, Verduin ML. Pharmacotherapy of comorbid mood, anxiety, and substance use disorders. Subst Use Misuse 2005; 40:2021.